Jeff Sharman M.D. is the medical director of hematology research for the US Oncology / Sarah Cannon Research Institute network. This consortium manages approximately one out of every five cancer patients treated in the United States and is the largest private research network in the country. 

Dr Sharman developed the original idea of using BTK inhibitors to treat lymphoid malignancies and conducted the first in human studies of ibrutinib within his private practice at the Willamette Valley Cancer and Research Center in Eugene, Oregon, US. 

Here Dr. Sharman addresses hypertension and arrhythmias related to BTK inhibitors.

Dr. Alexis Vasbinder, University of Washington School of Nursing, Seattle, USA

Read her article here:

https://www.jacc.org/doi/10.1016/j.jaccao.2023.07.007

Atrial Fibrillation and Anticoagulation are complex matters in cancer care. Dr. Abdel-Qadir provides a masterful summary of the key issues in this episode.

Prof Husam Abdel-Qadir, MD, Phd is a Cardiologist at Women’s College Hospital, Toronto, CA. Prof Abdel-Qadir's primary clinical and research focus is on the cardiovascular health of people with cancer, particularly breast cancer and he leads a research programme on the management and outcomes of people with atrial fibrillation.

Dr. Gagan Sahni Director of Cardio- Oncology and Inpatient Cardiology Consult services at Mount Sinai Hospital in NYC, and Fellow of ICOS presents her Center of Excellence quality improvement project.

Anecita Fadol who is Associate Professor, Education Director- Nursing Cardiology Program · The University of Texas MD Anderson Cancer Center and chair of the ICOS nurses Working Group

Jessica Coviello, DNP, APRN(Ct), ANP-BC, FAAN, Associate Dean of Faculty Development, Professor, Graduate Studies, Univ of TX School of Nursing in Houston

Dr. Carrie Lennemam, University of Alabama Birmingham explains how they are using AI to expedite referrals to their cardio-oncology clinic, saving time and saving lives.

Dr. Eric Yang, Director of Cardio-Oncology discusses how they have integrated cardio-oncology training into all aspects of their program for residents and fellows.

Dr Zsofia Drobni is a Cardiology Fellow at Semmelweis University, Budapest, HU. Her research focuses on the utility of cardiac CT and MRI in patients receiving cardiotoxic therapies, with a specific focus on immune checkpoint inhibitors. Dr Drobni graduated in 2017 from Semmelweis University, in Hungary, and continued her PhD studies at Semmelweis. Her PhD thesis was on “new perspectives of CT-based cardiovascular risk assessment”.

Dr Prince Otchere, MD, MPH is an Assistant Professor at the University of Texas Health where he co-directs the cardio-oncology programme.

Watch Full Webinar Here:

https://www.radcliffecardiology.com/webinars/cardiac-risk-prediction-model-patients-her-2-positive-breast-cancer-trastuzumab-therapy#

Read Dr. Otchere's award winning paper here:

https://cardiooncologyjournal.biomedcentral.com/articles/10.1186/s40959-023-00177-y

Dr Tamar Polonsky (The University of Chicago, US), explores the implications, diagnostic strategies and potential interventions for addressing incidental atherosclerosis in the journey of cancer care.

Watch Full Webinar Here:

https://www.radcliffecardiology.com/webinars/approach-incidental-atherosclerosis-cts-cancer-patients